Anaemia, Haemolytic
Description General Measures Medicine Treatment Referral/Consultation D55.0-3/D55.8-9/D56.0-4/D56.8-9/D58.0-2/D58.8-9/D59.0-6/D59.8-9 DESCRIPTION Anaemia due to destruction of red blood cells. Destruction may be due to: Extracellular factors such as auto-immunity or mechanical factors, e.g. disseminated intravascular coagulation (DIC), hypersplenism, mechanical heart valves. Abnormalities of the
D55.0-3/D55.8-9/D56.0-4/D56.8-9/D58.0-2/D58.8-9/D59.0-6/D59.8-9
DESCRIPTION
Anaemia due to destruction of red blood cells. Destruction may be due to:
- Extracellular factors such as auto-immunity or mechanical factors, e.g. disseminated intravascular coagulation (DIC), hypersplenism, mechanical heart valves.
- Abnormalities of the cell membrane, e.g. hereditary spherocytosis.
- Enzymes, e.g. G6PD deficiency.
- Haemoglobin abnormalities, e.g. sickle cell anaemia, thalassaemia.
- Thrombotic thrombocytopaenic purpura: TTP is a life-threatening emergency. Refer immediately to a specialist unit for plasma infusion or exchange (see: Thrombotic thrombocytopenic purpura-Haemolytic uraemic syndrome).
Investigations
- Evidence of haemolysis: anaemia, reticulocytosis, decreased haptoglobin, increased lactate dehydrogenase (LDH) and unconjugated hyperbilirubinaemia.
- FBC and peripheral smear: spherocytes often reported
- Coombs’ test (direct antiglobulin) is usually positive with autoimmune haemolysis.
- HIV status.
GENERAL MEASURES
- Treat the underlying cause.
- Do not transfuse prior to conducting appropriate investigations unless anaemia requires immediate intervention.
- In situations of life-threatening anaemia, transfuse the most compatible unit of red blood cells and get specialist advice urgently. Coombs-positive haemolytic anaemia may be technically difficult to cross match.
- Efficacy of transfusion is limited by the shortened red cell survival due to haemolysis.
- In G6PD deficiency, avoid drugs known to cause haemolysis, such as aspirin, sulphonamides (including co-trimoxazole), dapsone, methylene blue, and primaquine.
- In patients with cold agglutinins, all transfusions must be given through a blood warmer to avoid cold-induced haemolysis.
MEDICINE TREATMENT
Because of high red cell turnover, supplement with:
- Folic acid, oral, 5 mg daily.
Autoimmune haemolytic anaemia
Treat under specialist supervision.
- Prednisone, oral.
- Initial dose: 1 mg/kg daily, until Hb is stable and >10 g/dL.
- Taper slowly and monitor Hb at least once weekly. (Refer to Prescribing Information for Specific Medicines for an example of a dose reduction regimen).
- Glucocorticoids should be tapered slowly upon normalization of the haemoglobin and LDH. The patient should be monitored for recurrence following cessation of treatment.
- As these conditions can often be life-threatening, specialist advice should be sought as early as possible after diagnosis.
LoE:IIbix
REFERRAL/CONSULTATION
Indications of inadequate response:
- Haemolysis remains severe after 3 weeks of prednisone dosed at 1 mg/kg.
- Remission cannot be maintained on low doses of prednisone.
- The patient has intolerable adverse effects or contraindications to glucocorticoids.
Refer to specialist for second-line treatment:
- Immunosuppresive therapy – For specialist initiation.
- Splenectomy: Requires vaccination – see: Surgical prophylaxis.
LoE:IIIbx
Standard Treatment Guidelines And Essential Medicines List For South Africa, Adult Hospital level, 2020-4_Version 1_30 March 2026
Chapter 2: Blood and Blood Forming Organs; 2.1.4 Anaemia, Haemolytic
Drugs mentioned
ICD-10 codes
- D55.0Anaemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency
- D55.1Anaemia due to other disorders of glutathione metabolism
- D55.2Anaemia due to disorders of glycolytic enzymes
- D55.3Anaemia due to disorders of nucleotide metabolism
- D55.8Other anaemias due to enzyme disorders
- D55.9Anaemia due to enzyme disorder, unspecified
- D56.0Alpha thalassaemia
- D56.1Beta thalassaemia
- D56.2Delta-beta thalassaemia
- D56.3Thalassaemia trait
- D56.4Hereditary persistence of fetal haemoglobin [HPFH]
- D56.8Other thalassaemias
- D56.9Thalassaemia, unspecified
- D58.0Hereditary spherocytosis
- D58.1Hereditary elliptocytosis
- D58.2Other haemoglobinopathies
- D58.8Other specified hereditary haemolytic anaemias
- D58.9Hereditary haemolytic anaemia, unspecified
- D59.0Drug-induced autoimmune haemolytic anaemia
- D59.1Other autoimmune haemolytic anaemias
- D59.2Drug-induced nonautoimmune haemolytic anaemia
- D59.3Haemolytic-uraemic syndrome
- D59.4Other nonautoimmune haemolytic anaemias
- D59.5Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]
- D59.6Haemoglobinuria due to haemolysis from other external causes
- D59.8Other acquired haemolytic anaemias
- D59.9Acquired haemolytic anaemia, unspecified